COPENHAGEN, Denmark, September 10, 2024 / Biotech Newswire / -- Abacus Medicine Pharma Services (‘Abacus’) announces the signing of a partnership agreement with Mirum Pharmaceuticals, Inc. (‘Mirum’) for the commercialization of LIVMARLI® (maralixibat) oral solution in the Nordic markets. Under the terms of the agreement, Mirum has appointed Abacus to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.
LIVMARLI is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved with orphan designation in Europe to treat patients aged 2 months and older with cholestatic pruritus caused by Alagille syndrome (ALGS), as well as to treat patients aged 3 months and older with progressive familial intrahepatic cholestasis (PFIC). ALGS and PFIC are inherited, life-threatening rare diseases in which bile cannot drain properly from the liver, resulting in a build-up of bile acid in the liver and blood. This accumulation can cause progressive liver damage, cirrhosis, and end-stage liver disease.
Gary Kahn, Vice President of Business Development for Abacus Medicine Pharma Services, said: “We are thrilled to partner with Mirum Pharmaceuticals to introduce a treatment option for patients that suffer from these debilitating rare liver diseases. This partnership underscores the shared vision and joint commitment of both companies to bring a meaningful medication to those who need them most. Our combined expertise and resources will enable us to make substantial progress in addressing the challenges faced by the ALGS and PFIC communities in the Nordics.”
Nordics healthcare professionals can obtain details about LIVMARLI by contacting the Abacus Medicine Pharma Services medical team at: This email address is being protected from spambots. You need JavaScript enabled to view it.
Product information
Livmarli® 9.5 mg/mL oral solution (30 ml)
About Abacus Medicine Pharma Services
The Abacus Medicine Group was founded in 2004 to improve access to critical medicines throughout Europe, driven by the vision of supporting better healthcare and outcomes for patients with unmet medical needs. Abacus Medicine Pharma Services (AMPS) was launched in 2014 to provide bespoke, end-to-end commercialisation solutions for global innovators who want to successfully launch their assets in Europe. The combination of AMPS’ industry experience with the market-leading operational capabilities of the Group provides global biopharma organizations with a trusted framework for launching their innovative assets and achieving their commercial objectives.
For more information on Mirum Pharmaceuticals, Inc. please visit: https://www.mirumpharma.com
Contact
Abacus Medicine Pharma Services
Gary Kahn, Vice President of Business Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
+45 30 80 70 78
Keywords: Humans; Cholestasis, progressive familial intrahepatic 1; Bile; Alagille Syndrome; End Stage Liver Disease; Bile Acids and Salts; Sweden; Finland; Iceland; bile acid binding proteins; maralixibat; Rare Diseases; Cholestasis; Pruritus; Pharmaceutical Preparations; Liver Cirrhosis; Denmark; Cholestasis, Intrahepatic; Cholic Acid; Liver Diseases; Health Services Accessibility; Hospitalization; Marketing; Abacus Medicine Pharma Services; Mirum Pharmaceuticals; Livmarli®; Nordics (Denmark, Finland, Iceland, Norway, Sweden); Commercialization; Partnership agreement; Ileal bile acid transporter (IBAT) inhibitor; Alagille syndrome (ALGS); Progressive familial intrahepatic cholestasis (PFIC); Orphan designation; Rare liver diseases; Gary Kahn; Cholestatic pruritus; Bile acid build-up; End-stage liver disease
Source: Biotech Newswire